HHS' decision "could stagnate research that has the potential to save millions of lives," writes Simon Williams.

Q2 2025 Earnings Call Transcript August 14, 2025 Cellectar Biosciences, Inc. beats earnings expectations. Reported EPS is $-3 ...

August 14, 2025BioLineRx Ltd. misses on earnings expectations. Reported EPS is $-1 EPS, expectations were $-0.35. Operator: ...

GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2's formal safety review, it has advanced into Cohort 3 and ...

Results from the Phase II COLLECTiVE202 trial (NCT05370885) demonstrated a statistically significant difference between VE202 ...

August 14, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL ® siRNA gene silencing technology to ...

Key Points GAAP EPS for Q2 2025 missed analyst estimates, with a GAAP net loss of $2.2 million and a GAAP EPS of $(0.45). Clinical progress for lead candidate PH-762 showed positive safety and early ...

Key Points GAAP loss per share of $(0.47) for Q2 2025 was narrower than the $(0.53) analysts had expected, despite an ongoing absence of revenue. Research and development expenses (GAAP) increased 35.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...

PEMGARDA® (pemivibart) net product revenue of $11.8 million reported for Q2 2025, representing 413% growth year-over-yearInvivyd’s target of near-term profitability (1H 2025) was not met but remains ...

Traws Pharma, Inc. ( NASDAQ: TRAW) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Charles Parker - Interim Chief Financial Officer David Pauza - Corporate Participant Iain D. Dukes - ...

Management reiterated the expectation that Elfabrio royalties will exceed $100 million by 2030, based on a projected 15% to 20% market share of the Fabry disease market.